New drug obrixtamig targets Hard-to-Treat lung and neuroendocrine cancers in first human trial

NCT ID NCT04429087

Recruiting now Disease control Sponsor: Boehringer Ingelheim Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 24, 2026 · Updated 3 times

Summary

This early-phase study tests obrixtamig, a drug that helps the immune system attack cancer cells, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker called DLL3. Participants receive the drug weekly or every three weeks for up to 3 years. The main goal is to find the highest safe dose and schedule.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LARGE CELL NEUROENDOCRINE LUNG CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neuroendocrine carcinoma pulmonary large cell neuroendocrine carcinoma small cell carcinoma small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PATIENTS WITH SMALL CELL LUNG CARCINOMA AND OTHER NEOPLASMS SMALL CELL LUNG CARCINOMA AND OTHER NEUROENDOCRINE NEOPLASMS EXPRESSING DLL3

Contacts and locations

Locations

Clínica Universidad de Navarra
RECRUITING

Pamplona, 31008, Spain
Hospital Clinico Universitario de Valencia
RECRUITING

Valencia, 46010, Spain
Hospital Universitari Vall d'Hebron
RECRUITING

Barcelona, 08035, Spain
Hospital del Mar
RECRUITING

Barcelona, 08003, Spain
National Cancer Center Hospital East
RECRUITING

Chiba, Kashiwa, 277-8577, Japan
Technische Universität Dresden
RECRUITING

Dresden, 01307, Germany
University of Maryland School of Medicine
RECRUITING

Baltimore, Maryland, 21201, United States
University of Pittsburgh Medical Center
COMPLETED

Pittsburgh, Pennsylvania, 15232, United States
Universitätsklinikum Köln (AöR)
COMPLETED

Cologne, 50937, Germany
Universitätsklinikum Würzburg AÖR
RECRUITING

Würzburg, 97078, Germany
Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63108, United States
Winship Cancer Institute
RECRUITING

Atlanta, Georgia, 30322, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.